Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Saved in:
Bibliographic Details
Title: Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.
Authors: Naderi Z; Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.; School of Medicine, College of Health, Adelaide University, Adelaide, Australia., Sadras T; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia., Branford S; School of Medicine, College of Health, Adelaide University, Adelaide, Australia.; Department of Haematology and Bone Marrow Transplantation, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia., Shanmuganathan N; School of Medicine, College of Health, Adelaide University, Adelaide, Australia. Naranie.shanmuganathan@sa.gov.au.; Centre for Cancer Biology, SA Pathology, Adelaide, Australia. Naranie.shanmuganathan@sa.gov.au., Pagani IS; Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute, Adelaide, Australia.; School of Medicine, College of Health, Adelaide University, Adelaide, Australia.; Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
Source: Current hematologic malignancy reports [Curr Hematol Malig Rep] 2026 Apr 25; Vol. 21 (1). Date of Electronic Publication: 2026 Apr 25.
Publication Type: Journal Article; Review
Journal Info: Publisher: Current Science Country of Publication: United States NLM ID: 101262565 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-822X (Electronic) Linking ISSN: 15588211 NLM ISO Abbreviation: Curr Hematol Malig Rep Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-822X
DOI:10.1007/s11899-026-00778-1